ANALISIS KEPARAHAN INTERAKSI OBAT-OBAT POTENSIAL DI APOTEK DAERAH PESISIR PANTAI SURABAYA
DOI:
https://doi.org/10.30649/pst.v1i1.23Keywords:
Drug related problems, interaksi obat, efek samping obat, medication errorsAbstract
Potential drug-drug interactions (pDDIs) is one the drug related problems when two or more drugs given at the same time. DDIs are often predictable and avoidable. One of pharmacist roles is to assess prescription includes indication, dose, duplication therapy, adverse drug reaction, contraindication and DDIs, to identify, prevent and resolve DRPs. The objective of this study is to evaluate potential drug-drug interactions (pDDIs) in patients in east coast pharmacy in Surabaya. This study was performed by cross sectional of retrospective prescription in east coast pharmacy in Surabaya during March until May 2016. There were 780 prescriptions. Prevalence of pDDIs were 20,5%.Moderate pDDIs dominated 70% followed by minor (21%), major (8%) and contraindication (1%). The mechanisms of pDDIs is 82% by pharmacokinetic and 12% by pharmacodynamic. A Pharmacist should participate to identify and prevent harmful DDIs.
Downloads
References
Baxter I.A., Davis M., Driver S.,& Garner R. 2010. Stockley’s Drug Interactions. 9th ed. Pharmaceutical Press, London.
Cipolle R.J., Strand L.M.,&Morley P.C. 2012. Pharmaceutical Care Practice: The Patient-Centered Approach to Medication Management Services. 3th ed. McGraw-Hill, United States.
Mboi N. 2014. Peraturan Menteri Kesehatan Republik Indonesia Nomor 35 Tahun 2014 Tentang Standar Pelayanan Kefarmasian di Apotek. Menteri Kesehatan Republik Indonesia, Jakarta. Pp 11-12
Dirin MM, Mousavi S, Afshari AR, Tabrizian K, Ashrafi MH., 2014. Potential drug-drug interactions in prescriptions dispensed in community and hospital pharmacies in East of Iran. Journal of research in pharmacy practice. 3(3): 104.
MousaviS, Norouzi M, Ashouri A, Javadi MR, Gholami K, Hadjibabaie, M., 2014. Study of Potential Drug-Drug Interaction in Prescriptions of University –Based Pharmacies. Journal of Pharmaceutical Care. 2(2): 60-65.
Corsini A, Bellosta S, Davidson MH., 2005. Pharmacokinetic interactions between statins and fibrates. The American journal of cardiology. 96(9): 44-49.
Omar MA, Wilson J, Cox TS., 2001. Rhabdomyolysis and HMG-CoA reductase inhibitors. Annals of Pharmacotherapy. 35(9): 1096-1107.
Wierzbicki AS, Mikhailidis DP, Wray R, et al., 2003. Statin-fibrate combination therapy for hyperlipidaemia: a review. Current medical research and opinion. 19(3): 155-168.
Cupp M. Clinically Significant Statin Drug Interactions. [diunduh 11 Desember 2017]. Tersedia dari http://pharmacistsletter.therapeuticresearch.com/pl/ArticleDD.aspx?nidchk=1&cs=&s=PL&pt=2&fpt=2&segment=4421&dd=280606.
Alawiyah TB., 2012. Evaluasi Penggunaan Obat Antituberkulosis Pada Pasien Tuberkulosis Dewasa Diinstalasi Rawat Jalan RS Paru Dungus Madiun Tahun 2010, Thesis, Universitas Muhammadiyah Surakarta.
Khalili H, Dashti-Khavidaki S, Rasoolinejad M, et al., 2015. Anti-tuberculosis drugs related hepatotoxicity; incidence, risk factors, pattern of changes in liver enzymes and outcome. DARU Journal of Pharmaceutical Sciences. 17(3): 163-167.
Tostmann A, Boeree, MJ, Aarnoutse RE, et al., 2008. Antituberculosis drug‐induced hepatotoxicity: concise up‐to‐date review. Journal of gastroenterology and hepatology. 23(2): 192-202.
Egger SS, Drewe J, Schlienger RG., 2003. Potential drug–drug interactions in the medication of medical patients at hospital discharge. European journal of clinical pharmacology. 58(11): 773-778.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 JOURNAL OF PHARMACY SCIENCE AND TECHNOLOGY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
